NCT05092165CompletedPhase 2
Methylene Blue for the Prevention of Hypotension During Hemodialysis
Prospective, Randomized, Controlled Trial Assessing the Effects of Methylene Blue for the Prevention of Hypotension During Renal Replacement Therapy
Source: ClinicalTrials.gov · Last updated 17 Apr 2026
Brief summary (registry, in English)
Hypotension is a common complication of intermittent renal replacement therapy. Methylene blue, an inhibitor of nitric oxide synthesis, has been suggested to improve hemodynamics during renal replacement therapy in ambulatory patients, but evidence is lacking for critically ill patients. This trial will assess whether methylene blue can improve hemodynamics and blood pressure for patients with shock requiring renal replacement therapy.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 261 (actual)
- First submitted
- 13 Oct 2021
- Start date
- Oct 2021
- Primary completion date
- Dec 2025
- Lead sponsor
- Federal University of São Paulo
- Diseases
- High blood pressure
- NCT number
- NCT05092165
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 261
- From Oct 2021 to the primary completion date, Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior participation in the study
Other illness
- Known allergy to methylene blue
- Acute coronary syndrome
Lab values
- Known Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Other
- Pregnancy
- Life expectancy less than 24 hours
- Exclusive palliative or end-of-life care
- RRT due to hypertensive crisis
- Chronic nitrate oral use
Who the study is looking for
- Patients over 18 years old
- Acute kidney injury or acute-on-chronic kidney disease requiring intermittent renal replacement therapy hemodialysis
- Systolic blood pressure lower than 100 mmHg or use of vasopressor
- Signed informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Federal University of Sao Paulo Coordinator of this site? Confirm its status | São Paulo | Brazil | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.